Relmada Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Cash & Equivalents	3.5	3.86	4.09	5.4	44.44	Upgrade
Short-Term Investments	89.51	41.05	92.23	142.93	167.47	Upgrade
Cash & Short-Term Investments	93.01	44.91	96.32	148.32	211.91	Upgrade
Cash Growth	107.10%	-53.38%	-35.06%	-30.01%	80.98%	Upgrade
Other Receivables	-	-	-	0.51	0.09	Upgrade
Receivables	-	-	-	0.51	0.09	Upgrade
Prepaid Expenses	0.98	0.89	1.19	4.04	11.3	Upgrade
Total Current Assets	93.98	45.8	97.51	152.87	223.3	Upgrade
Other Long-Term Assets	0.02	0.02	0.04	0.03	0.03	Upgrade
Total Assets	94	45.82	97.55	152.91	223.33	Upgrade
Accounts Payable	1.57	4.13	3.51	5.26	11.19	Upgrade
Accrued Expenses	4.86	6.16	8.69	7.21	3.87	Upgrade
Total Current Liabilities	6.43	10.29	12.19	12.47	15.06	Upgrade
Other Long-Term Liabilities	1.06	0	-	-	-	Upgrade
Total Liabilities	7.49	10.3	12.19	12.47	15.06	Upgrade
Common Stock	0.07	0.03	0.03	0.03	0.03	Upgrade
Additional Paid-In Capital	784.71	676.37	646.23	602.52	513.3	Upgrade
Retained Earnings	-698.27	-640.88	-560.9	-462.11	-305.07	Upgrade
Shareholders' Equity	86.51	35.52	85.36	140.44	208.26	Upgrade
Total Liabilities & Equity	94	45.82	97.55	152.91	223.33	Upgrade
Net Cash (Debt)	93.01	44.91	96.32	148.32	211.91	Upgrade
Net Cash Growth	107.10%	-53.38%	-35.06%	-30.01%	80.98%	Upgrade
Net Cash Per Share	2.36	1.49	3.20	5.01	12.07	Upgrade
Filing Date Shares Outstanding	104.89	33.19	30.17	30.1	29.37	Upgrade
Total Common Shares Outstanding	73.33	30.1	30.1	30.1	27.74	Upgrade
Working Capital	87.55	35.5	85.31	140.4	208.24	Upgrade
Book Value Per Share	1.18	1.18	2.84	4.67	7.51	Upgrade
Tangible Book Value	86.51	35.52	85.36	140.44	208.26	Upgrade
Tangible Book Value Per Share	1.18	1.18	2.84	4.67	7.51	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.